AU2013204731C1 - Therapeutic compounds - Google Patents

Therapeutic compounds Download PDF

Info

Publication number
AU2013204731C1
AU2013204731C1 AU2013204731A AU2013204731A AU2013204731C1 AU 2013204731 C1 AU2013204731 C1 AU 2013204731C1 AU 2013204731 A AU2013204731 A AU 2013204731A AU 2013204731 A AU2013204731 A AU 2013204731A AU 2013204731 C1 AU2013204731 C1 AU 2013204731C1
Authority
AU
Australia
Prior art keywords
cobicistat
tenofovir alafenamide
pharmaceutically acceptable
alafenamide hemifumarate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013204731A
Other languages
English (en)
Other versions
AU2013204731A1 (en
AU2013204731B2 (en
Inventor
Srinivasan Ramanathan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AU2013204731A1 publication Critical patent/AU2013204731A1/en
Application granted granted Critical
Publication of AU2013204731B2 publication Critical patent/AU2013204731B2/en
Priority to AU2016203666A priority Critical patent/AU2016203666A1/en
Publication of AU2013204731C1 publication Critical patent/AU2013204731C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013204731A 2012-02-03 2013-02-01 Therapeutic compounds Active AU2013204731C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016203666A AU2016203666A1 (en) 2012-02-03 2016-06-02 Therapeutic compounds

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261594894P 2012-02-03 2012-02-03
US61/594,894 2012-02-03
US201261618411P 2012-03-30 2012-03-30
US61/618,411 2012-03-30
US201261624676P 2012-04-16 2012-04-16
US61/624,676 2012-04-16
US201261692392P 2012-08-23 2012-08-23
US61/692,392 2012-08-23
US201261737493P 2012-12-14 2012-12-14
US61/737,493 2012-12-14
PCT/US2013/024438 WO2013116720A1 (en) 2012-02-03 2013-02-01 Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016203666A Division AU2016203666A1 (en) 2012-02-03 2016-06-02 Therapeutic compounds

Publications (3)

Publication Number Publication Date
AU2013204731A1 AU2013204731A1 (en) 2013-08-22
AU2013204731B2 AU2013204731B2 (en) 2016-03-03
AU2013204731C1 true AU2013204731C1 (en) 2017-08-31

Family

ID=47722563

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013204731A Active AU2013204731C1 (en) 2012-02-03 2013-02-01 Therapeutic compounds
AU2013204727A Abandoned AU2013204727A1 (en) 2012-02-03 2013-02-01 Therapeutic compounds
AU2016203666A Abandoned AU2016203666A1 (en) 2012-02-03 2016-06-02 Therapeutic compounds

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2013204727A Abandoned AU2013204727A1 (en) 2012-02-03 2013-02-01 Therapeutic compounds
AU2016203666A Abandoned AU2016203666A1 (en) 2012-02-03 2016-06-02 Therapeutic compounds

Country Status (15)

Country Link
US (2) US20150105350A1 (cg-RX-API-DMAC7.html)
EP (1) EP2809323A1 (cg-RX-API-DMAC7.html)
JP (1) JP6059255B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140119177A (cg-RX-API-DMAC7.html)
CN (1) CN104105484A (cg-RX-API-DMAC7.html)
AU (3) AU2013204731C1 (cg-RX-API-DMAC7.html)
BR (1) BR112014018918A8 (cg-RX-API-DMAC7.html)
CA (1) CA2863662A1 (cg-RX-API-DMAC7.html)
EA (1) EA026138B1 (cg-RX-API-DMAC7.html)
HK (2) HK1202801A1 (cg-RX-API-DMAC7.html)
IL (1) IL233874A0 (cg-RX-API-DMAC7.html)
MD (1) MD20140091A2 (cg-RX-API-DMAC7.html)
MX (1) MX2014009172A (cg-RX-API-DMAC7.html)
NZ (1) NZ629896A (cg-RX-API-DMAC7.html)
WO (2) WO2013116730A1 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3150586T (pt) 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
AP3639A (en) * 2011-08-16 2016-03-13 Gilead Sciences Inc Tenofovir alafenamide hemifumarate
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
HK1220390A1 (zh) * 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨,替诺福韦,达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
IN2013CH05455A (cg-RX-API-DMAC7.html) * 2013-11-27 2015-08-07 Laurus Labs Private Ltd
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
EP3129009A1 (en) * 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN105518011B (zh) * 2014-04-21 2018-07-27 四川海思科制药有限公司 氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
SI3166607T1 (sl) * 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
CN105237571B (zh) * 2014-11-28 2018-03-09 成都苑东生物制药股份有限公司 9‑[(r)‑2‑[[(s)‑[[(s)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐
JP2017536403A (ja) * 2014-12-04 2017-12-07 アイガー・バイオファーマシューティカルズ・インコーポレイテッドEiger Biopharmaceuticals, Inc. デルタ肝炎ウイルス感染の治療
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
AU2015373104B2 (en) * 2015-01-03 2020-07-09 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
CN104817593B (zh) * 2015-04-27 2016-11-16 广州同隽医药科技有限公司 半富马酸替诺福韦艾拉酚胺关键中间体的合成工艺
EP4233846B1 (en) * 2015-06-30 2024-12-04 Gilead Sciences, Inc. Pharmaceutical formulations
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
US9598459B2 (en) 2015-08-03 2017-03-21 Pop Test Oncology Llc Pharmaceutical compositions and methods
CN105153231A (zh) * 2015-08-28 2015-12-16 浙江车头制药股份有限公司 一种一苯基pmpa的制备方法
CN113546052A (zh) 2015-11-09 2021-10-26 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
AU2017218800B2 (en) * 2016-02-12 2022-09-22 Cipla Limited Pharmaceutical compositions comprising an anti-retroviral drug and a pharmacokinetic enhancer
CN107179355B (zh) * 2016-03-11 2021-08-10 广东东阳光药业有限公司 一种分离检测替诺福韦艾拉酚胺及其有关物质的方法
WO2018039157A1 (en) * 2016-08-25 2018-03-01 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
CN108070003A (zh) * 2016-12-02 2018-05-25 上海博志研新药物技术有限公司 替诺福韦艾拉酚胺半反丁烯二酸盐晶型及制备方法和应用
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
RU2647576C1 (ru) * 2017-02-28 2018-03-16 Васильевич Иващенко Александр Циклобутил (S)-2-[[[(R)-2-(6-аминопурин-9-ил)-1-метил-этокси]метил-фенокси-фосфорил]амино]-пропаноаты, способ их получения и применения
CN106928277A (zh) * 2017-03-16 2017-07-07 江苏诚信药业有限公司 一种替诺福韦艾拉酚胺合成的工艺方法
US11191763B2 (en) 2017-03-20 2021-12-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HIV post-exposure prophylaxis
RU2019136678A (ru) * 2017-04-18 2021-05-18 Сипла Лимитед Комбинированная терапия для применения в лечении ретровирусных инфекций
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
EP3700573A1 (en) * 2017-10-24 2020-09-02 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
CN110305163A (zh) * 2018-03-27 2019-10-08 北京济美堂医药研究有限公司 替诺福韦艾拉酚胺半富马酸盐的制备方法
CN108484672A (zh) * 2018-05-23 2018-09-04 中国药科大学制药有限公司 磷丙替诺福韦的手性拆分方法
CN109081853A (zh) * 2018-09-03 2018-12-25 南京正大天晴制药有限公司 一种磷丙替诺福韦有关物质的制备方法
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
EP3989956A1 (en) * 2019-06-28 2022-05-04 Anhui Ronghang Biotech Development Co., Ltd. Compositions and methods for treatment of hepatitis b virus infection
AU2020318808A1 (en) 2019-07-19 2022-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV pre-exposure prophylaxis
CN111606949A (zh) * 2020-03-13 2020-09-01 浙江车头制药股份有限公司 一种磷丙替诺福韦杂质的制备方法
CN111303209A (zh) * 2020-03-21 2020-06-19 石家庄龙泽制药股份有限公司 一种丙酚替诺福韦降解杂质的制备方法
US20240009214A1 (en) * 2020-12-02 2024-01-11 Cipla Limited Method of Treating Viral Infection
WO2024196814A1 (en) 2023-03-17 2024-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration
EP4640214A1 (en) * 2024-03-28 2025-10-29 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A tablet comprising tenofovir alafenamide monofumarate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010091197A2 (en) * 2009-02-06 2010-08-12 Gilead Sciences, Inc. Tablets for combination therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB453061A (en) 1935-03-23 1936-09-04 Charles Howard Twigg Improvements in and relating to gas heated geysers and water heaters
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
HRP20030047B1 (hr) 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
DE10153078A1 (de) 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
PT3150586T (pt) * 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
US8354421B2 (en) 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors
AP3639A (en) * 2011-08-16 2016-03-13 Gilead Sciences Inc Tenofovir alafenamide hemifumarate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010091197A2 (en) * 2009-02-06 2010-08-12 Gilead Sciences, Inc. Tablets for combination therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELION, R., et al., AIDS, 2011, vol. 25(15), pages 1881-1886 *
Phase II trial investigates GS-7340 as part of a new treatment regimen", Thomson Reuters Drug News, 26 January 2012 *

Also Published As

Publication number Publication date
IL233874A0 (en) 2014-09-30
US20170056423A1 (en) 2017-03-02
JP2015505565A (ja) 2015-02-23
BR112014018918A2 (cg-RX-API-DMAC7.html) 2017-06-20
NZ629896A (en) 2016-03-31
BR112014018918A8 (pt) 2017-07-11
CA2863662A1 (en) 2013-08-08
JP6059255B2 (ja) 2017-01-11
HK1204914A1 (en) 2015-12-11
EA201491287A1 (ru) 2015-04-30
AU2013204731A1 (en) 2013-08-22
EA026138B1 (ru) 2017-03-31
US20150105350A1 (en) 2015-04-16
AU2013204731B2 (en) 2016-03-03
HK1202801A1 (en) 2015-10-09
MX2014009172A (es) 2014-08-27
WO2013116720A1 (en) 2013-08-08
AU2013204727A1 (en) 2013-08-22
AU2016203666A1 (en) 2016-06-23
MD20140091A2 (ro) 2015-01-31
CN104105484A (zh) 2014-10-15
KR20140119177A (ko) 2014-10-08
EP2809323A1 (en) 2014-12-10
WO2013116730A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
AU2013204731B2 (en) Therapeutic compounds
WO2013115916A1 (en) Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
TWI496778B (zh) 用於改善被細胞色素p450單氧合酶所代謝之治療劑的藥物動力性質之調節劑
ES2602784T3 (es) Moduladores de las propiedades farmacocinéticas de los agentes terapéuticos
JP5629585B2 (ja) シトクロムp450のインヒビター
US20150004239A1 (en) Pharmaceutical compositions and methods for their preparation
US8951986B2 (en) Salts of HIV inhibitor compounds
US20110223131A1 (en) Antiviral compounds
US20140187771A1 (en) Amorphous solid salts
NO20200578A1 (no) Modulatorer av farmakokinetikkegenskaper til terapeutika
AU2019216697A1 (en) Modulators of pharmacokinetic properties of therapeutics
HK40000258A (en) Combination formulation of three antiviral compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 APR 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 APR 2017